Cargando…
Preclinical Evaluation of TB/FLU-04L—An Intranasal Influenza Vector-Based Boost Vaccine against Tuberculosis
Tuberculosis is a major global threat to human health. Since the widely used BCG vaccine is poorly effective in adults, there is a demand for the development of a new type of boost tuberculosis vaccine. We designed a novel intranasal tuberculosis vaccine candidate, TB/FLU-04L, which is based on an a...
Autores principales: | Shurygina, Anna-Polina, Zabolotnykh, Natalia, Vinogradova, Tatiana, Khairullin, Berik, Kassenov, Markhabat, Nurpeisova, Ainur, Sarsenbayeva, Gulbanu, Sansyzbay, Abylai, Vasilyev, Kirill, Buzitskaya, Janna, Egorov, Andrey, Stukova, Marina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138401/ https://www.ncbi.nlm.nih.gov/pubmed/37108602 http://dx.doi.org/10.3390/ijms24087439 |
Ejemplares similares
-
Enhancement of the Local CD8(+) T-Cellular Immune Response to Mycobacterium tuberculosis in BCG-Primed Mice after Intranasal Administration of Influenza Vector Vaccine Carrying TB10.4 and HspX Antigens
por: Vasilyev, Kirill, et al.
Publicado: (2021) -
Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan
por: Zakarya, Kunsulu, et al.
Publicado: (2021) -
Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up
por: Khairullin, Berik, et al.
Publicado: (2022) -
Intranasal Immunization with the Influenza A Virus Encoding Truncated NS1 Protein Protects Mice from Heterologous Challenge by Restraining the Inflammatory Response in the Lungs
por: Vasilyev, Kirill, et al.
Publicado: (2021) -
Influenza viral vectors expressing the Brucella OMP16 or L7/L12 proteins as vaccines against B. abortus infection
por: Tabynov, Kaissar, et al.
Publicado: (2014)